entertainment -WSS

entertainment

author：leisure time 2025-09-27 12:56:12 - browse：925

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： FDA panel signals lack of confidence in Amgen cancer drug data

entertainment

WSS

After Optum profits sink, UnitedHealth makes changes

Bill would stop addiction treatment from triggering child abuse inquiry

YouTube cracks down on misinformation on cancer treatment

Chemotherapy drug shortage eases slightly but still widespread

AI can decode, harness the power of the humane immune system

Senators push IRS to launch nonprofit hospital probe

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What to know about the judge who will handle the Trump case

Apple is now the first public company to be valued at $3 trillion

Histogen: Failed biotech offers rare public look inside

Peter Hotez and the public health issue of online harassment

A virus, fished out of a lake, may have saved a man’s life

Activists slam private health insurers over coverage restrictions

Stroke deaths set to near 10 million globally by 2050

In age of alternative facts, a scholarly course on calling out crap

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

leisure time

Phenylephrine and the overlooked value of the placebo effect

Biden administration begins canceling student loan debt for 804,000 borrowers

FDA authorizes Novavax’s updated Covid

Liquid biopsy for lung cancer is launched by Delfi

Phenylephrine and the overlooked value of the placebo effect

Bird flu researchers hone in on Finland’s mink farms

hotspot

knowledge

entertainment

entertainment